tetano
Editor, Senior Moderator
Diabetes Obes Metab. 2020 May 14. doi: 10.1111/dom.14086. [Epub ahead of print]
The Clinical Characteristics and Outcomes of Diabetes Mellitus and Secondary Hyperglycaemia Patients with Coronavirus Disease 2019: a Single-center, Retrospective, Observational Study in Wuhan.
Zhang Y[SUP]1[/SUP], Li H[SUP]2[/SUP], Zhang J[SUP]1[/SUP], Cao Y[SUP]1[/SUP], Zhao X[SUP]1[/SUP], Yu N[SUP]1[/SUP], Gao Y[SUP]1[/SUP], Ma J[SUP]2[/SUP], Zhang H[SUP]2[/SUP], Zhang J[SUP]1[/SUP], Guo X[SUP]1[/SUP], Liu X[SUP]3[/SUP].
Author information
Abstract
AIMS:
Since the pandemic outbreak of COVID-19, limited information is available on diabetic patients with COVID-19.
MATERIALS AND METHODS:
We retrospectively analysed 166 COVID-19 patients at Tongji Hospital (Wuhan) from February 8 to March 21, 2020. Clinical characteristics and outcomes (as of April 4, 2020) were compared among control (group 1), secondary hyperglycaemia (group 2: no diabetes history, FPG levels ≥7.0 mmol/L once and HbA1c values <6.5%) and diabetic (group 3) patients.
RESULTS:
Compared to group 1, groups 2 and 3 had higher rates of leukocytosis, neutrophilia, lymphocytopenia, eosinopenia, and levels of sCRP, ferritin and d-dimer (P < 0.05 for all). Group 2 patients have higher levels of LDH, prevalence of liver dysfunction and increased IL-8 than those in group 1, a higher prevalence of increased IL-8 was found in group 2 than in group 3 (P < 0.05 for all). The proportions of critical patients in groups 2 and 3 were significantly higher compared to group 1 (38.1%, 32.8% vs. 9.5%, P < 0.05 for both). Groups 2 and 3 had significantly longer hospital stays than group 1, which was nearly one week longer. The composite outcomes risks were 5.47 (1.56-19.82) and 2.61 (0.86-7.88) times greater in group 2 and 3 than in group 1.
CONCLUSIONS:
Hyperglycemia in both diabetes and secondary hyperglycemia patients with COVID-19 may indicate poor prognoses. There were differences between secondary hyperglycemia and diabetes patients. We recommend that clinicians pay more attention to the blood glucose status of COVID-19 patients, even those not diagnosed with diabetes before admission.
This article is protected by copyright. All rights reserved.
PMID:32406594DOI:10.1111/dom.14086
The Clinical Characteristics and Outcomes of Diabetes Mellitus and Secondary Hyperglycaemia Patients with Coronavirus Disease 2019: a Single-center, Retrospective, Observational Study in Wuhan.
Zhang Y[SUP]1[/SUP], Li H[SUP]2[/SUP], Zhang J[SUP]1[/SUP], Cao Y[SUP]1[/SUP], Zhao X[SUP]1[/SUP], Yu N[SUP]1[/SUP], Gao Y[SUP]1[/SUP], Ma J[SUP]2[/SUP], Zhang H[SUP]2[/SUP], Zhang J[SUP]1[/SUP], Guo X[SUP]1[/SUP], Liu X[SUP]3[/SUP].
Author information
Abstract
AIMS:
Since the pandemic outbreak of COVID-19, limited information is available on diabetic patients with COVID-19.
MATERIALS AND METHODS:
We retrospectively analysed 166 COVID-19 patients at Tongji Hospital (Wuhan) from February 8 to March 21, 2020. Clinical characteristics and outcomes (as of April 4, 2020) were compared among control (group 1), secondary hyperglycaemia (group 2: no diabetes history, FPG levels ≥7.0 mmol/L once and HbA1c values <6.5%) and diabetic (group 3) patients.
RESULTS:
Compared to group 1, groups 2 and 3 had higher rates of leukocytosis, neutrophilia, lymphocytopenia, eosinopenia, and levels of sCRP, ferritin and d-dimer (P < 0.05 for all). Group 2 patients have higher levels of LDH, prevalence of liver dysfunction and increased IL-8 than those in group 1, a higher prevalence of increased IL-8 was found in group 2 than in group 3 (P < 0.05 for all). The proportions of critical patients in groups 2 and 3 were significantly higher compared to group 1 (38.1%, 32.8% vs. 9.5%, P < 0.05 for both). Groups 2 and 3 had significantly longer hospital stays than group 1, which was nearly one week longer. The composite outcomes risks were 5.47 (1.56-19.82) and 2.61 (0.86-7.88) times greater in group 2 and 3 than in group 1.
CONCLUSIONS:
Hyperglycemia in both diabetes and secondary hyperglycemia patients with COVID-19 may indicate poor prognoses. There were differences between secondary hyperglycemia and diabetes patients. We recommend that clinicians pay more attention to the blood glucose status of COVID-19 patients, even those not diagnosed with diabetes before admission.
This article is protected by copyright. All rights reserved.
PMID:32406594DOI:10.1111/dom.14086